Geistlich Pharma AG   Report issue

For profit Phase 2
Founded: Wolhusen Switzerland (1851)
Status: No NME R&D (1851)

Organization Overview

First Clinical Trial
2015
NCT02313883
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Geistlich Pharma AG

Active Ingredients

Drugs in Phase 2 Trials (3)

gp-2250 (1 trial)

taurolidine (1 trial)

tauroline (1 trial)

Drugs in Other Trials (2)

collagen (1 trial)

toluidine blue (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Periodontitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5